---
title: "Varegacestat (AL102) in Desmoid tumors: Nonsteroidal anti-inflammatory drugs and hormonal therapy"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Nonsteroidal anti-inflammatory drugs and hormonal therapy. Topics: Desmoid Tumor Working Group position on antihormonal therapies and NSAIDs; Hormone antagonists no longer recommended by the Desmoid Tumor Working Group; NCCN placement of NSAIDs for pain as quoted in a payer policy; European consensus position on antihormonal therapy, 2017, superseded in 2020; 8 further topics. 12 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/nonsteroidal-anti-inflammatory-drugs-and-hormonal-therapy"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Nonsteroidal anti-inflammatory drugs and hormonal therapy

<a id="heading-2.2.2.1.8"></a>

## 2.2.2.1.8 Nonsteroidal Anti-inflammatory Drugs and Hormonal Therapy

<a id="topic-2.2.2.1.8-1"></a>

### Desmoid Tumor Working Group position on antihormonal therapies and NSAIDs

> “Beside retrospective case series showing some evidence of activity, some with response rates of 25% with prolonged disease control in as many as 90% of patients, the only prospective phase II study evaluating antihormonal therapy plus NSAID showed limited activity as measured by WHO response criteria and PFS rates. Moreover, a recently published paper found no clear relationship between size, MRI signal changes and symptom changes with tamoxifen treatment [41]. Therefore, there is no evidence to consider antihormonal therapies and NSAIDs in patients with DT.”

Source: [Desmoid Tumor Working Group (2020)](https://www.ejcancer.com/article/S0959-8049%2819%2930832-9/fulltext)

<a id="topic-2.2.2.1.8-2"></a>

### Hormone antagonists no longer recommended by the Desmoid Tumor Working Group

> “Note that nirogacestat was not approved for use at the time of survey completion [18], and hormone antagonists are no longer recommended by Desmoid Tumor Working Group Consenus Guidelines [13]”
> “The use of NSAIDs and hormone antagonists reported in this study is only recommended for certain circumstances by evidence-based guidelines [14, 16].”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.2.1.8-3"></a>

### NCCN placement of NSAIDs for pain as quoted in a payer policy

> “Sulindac or other nonsteroidal”
> “including celecoxib, are recommended for pain under”
> “Useful in Certain Circumstances”
> “(category 2A).”

Source: [Cigna nirogacestat coverage policy (2025)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_832_coveragepositioncriteria_oncology_ogsiveo_pa.pdf)

<a id="topic-2.2.2.1.8-4"></a>

### European consensus position on antihormonal therapy, 2017, superseded in 2020

> “Anti-hormonal agents such as tamoxifen may be used—alone [60] or in combination with NSAIDs [61]—as first medical treatment, mainly because of their limited toxicity, rare adverse events and low costs [62] (III, B). However, response rates have been found to be low and no clear relationship between symptom changes, size or MRI signal changes could be demonstrated [63]. Therefore, a general recommendation for its use cannot be given.”

Source: [Kasper et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5834048/)

<a id="topic-2.2.2.1.8-5"></a>

### High-dose tamoxifen plus sulindac in a German institutional series

> “Since 1992, 25 patients at Heinrich Heine University (Dusseldorf, Germany) were treated with a combination of tamoxifen and sulindac.”
> “In the current study, 17 patients with FAP-associated and 8 patients with sporadic desmoid tumors received 120 mg of tamoxifen and 300 mg of sulindac daily.”
> “Of the group of patients who received tamoxifen and sulindac as a primary treatment, all three patients with sporadic desmoid tumors demonstrated cessation of growth, and 10 of the 13 patients with FAP-associated tumors achieved either a PR or CR.”
> “Based on this experience, the authors recommended high-dose tamoxifen and sulindac as the primary treatment for patients with FAP-associated desmoid tumors.”

Source: [Hansmann et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/14745880/)

<a id="topic-2.2.2.1.8-6"></a>

### High-dose selective estrogen receptor modulators plus sulindac in an institutional cohort

> “This study included all desmoid patients that were treated and followed at our institution and had completed at least 1 year of treatment.”
> “A total of 134 patients were included. 64 (47.8 %) patients had a confirmed diagnosis of FAP, 69 (51.5 %) patients were sporadic. Overall 114 (85.1 %) patients showed regressive or stable desmoid size.”
> “Response was defined as stable size or regression of desmoid size between two CT or MRI scans.”

Source: [Quast et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26275868/)

<a id="topic-2.2.2.1.8-7"></a>

### Tamoxifen plus sulindac in children in a Children's Oncology Group phase 2 study

> “We evaluated the safety and efficacy of tamoxifen and sulindac in a prospective phase II study within the Children’s Oncology Group.”
> “No life-threatening toxicity was reported. Twelve (40%) of 30 females developed ovarian cysts, which were asymptomatic in 11 cases. Ten patients completed therapy without disease progression or discontinuing treatment. Responses included four partial and one complete (5/59, 8%). The estimated 2-year PFS and survival rates were 36% (95% confidence interval: 0.23–0.48) and 96%, respectively.”
> “However, the combination showed relatively little activity as measured by response and PFS rates.”

Source: [Skapek et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4646066/)

<a id="topic-2.2.2.1.8-8"></a>

### Toremifene in a retrospective reference-institution series

> “We retrospectively reviewed all patients treated with toremifene between 2005 and 2012 at a reference institution.”
> “Forty-four patients were treated with toremifene 180 mg daily, 20 for radiological progression, 16 for pain and 8 for both.”
> “PFS was 89.6% at 2 years. According to Response Evaluation Criteria in Solid Tumours, partial response, stable disease and disease progression were observed in 25%, 65% and 10% of the patients, respectively. Symptomatic relief was obtained in 75% of patients.”
> “Adverse events G≥2 according to National Cancer Institute Common Toxicity Criteria were recorded in ten patients.”

Source: [Fiore et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26602014/)

<a id="topic-2.2.2.1.8-9"></a>

### Toremifene at two dose levels in a prospective phase 2 study

> “In order to test the dose efficacy and assess activity and safety of toremifene in DF, we conducted this prospective phase 2 study (NCT02353429).”
> “The 6 and 12 months progression-free survival (PFS) probability was 14.4% (95% CI, 5.1-41.1) and 4.8% (95% CI, 0.7-32.6) for patients receiving 60 mg compared with 72.0% (95% CI, 54.2-96.2) and 52.5% (95% CI, 33.1-83.3) for those receiving 180 mg.”
> “No toremifene-related serious adverse events were observed.”
> “Toremifene at 60 mg daily is ineffective in this patient population. However, clinical benefit was observed at 180 mg in selected cases.”

Source: [Colombo et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41903360/)

<a id="topic-2.2.2.1.8-10"></a>

### Systematic review of anti-oestrogen therapy

> “Data on 168 DTs treated with anti-oestrogen agents, alone or in combination with nonsteroidal anti-inflammatory drugs, were identified with an overall response rate of 51%. There was no difference in response according to the type of DTs or between different anti-oestrogen therapies. Combination with anti-inflammatory drugs did not improve the outcome.”
> “Despite potential inaccuracies in the methodology, the results of the review indicate that anti-oestrogen therapy produces some effect in about one half of patients with DTs.”

Source: [Bocale et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21831172/)

<a id="topic-2.2.2.1.8-11"></a>

### Meloxicam response and CTNNB1 mutation status

> “Of the 33 patients with meloxicam treatment, one showed complete remission (CR), 7 partial remission (PR), 12 stable disease (SD), and 13 progressive disease (PD).”
> “S45F mutation was significantly associated with a poor response (all cases; PD) (p = 0.017), whereas the other mutations had no impact on efficacy.”

Source: [Hamada et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4006838/)

<a id="topic-2.2.2.1.8-12"></a>

### NSAID and hormone antagonist agents reported by study participants

| Systemic treatments | n (%) |
| --- | --- |
| “NSAIDS (with sulindac and celecoxib)” | “112 (40)” |
| “Sulindac” | “46 (41)” |
| “Celecoxib” | “23 (21)” |
| “Hormone antagonists” | “47 (17)” |
| “Antihormonal agent (e.g., tamoxifen)” | “41 (87)” |
| “Toremifene” | “4 (9)” |

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

Additional sources: [Kasper et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38900421/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
